BAJAJ BROKING

Notification close image
No new Notification messages
card image
Vikram Solar IPO is Open!
Apply for the Vikram Solar IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

714

540797

SHALBY

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Shalby performance

Today’s low

Today’s high

₹ 201.11 ₹ 206.52
₹ 202.08

52 week low

52 week high

₹ 177.25 ₹ 297.90
₹ 202.08

Open Price

₹ 205.00

Prev. Close

₹ 203.20

Volume (Shares)

101237.00

Total traded value

₹ 204.57

Upper Circuit

₹ 243.84

Lower Circuit

₹ 162.56

info

Shalby Share Price Update

As of the latest trading session, Shalby share price is currently at ₹ 202.08, which is down by ₹ -1.11 from its previous closing. Today, the stock has fluctuated between ₹ 201.11 and ₹ 206.52. Over the past year, Shalby has achieved a return of -19.62 %. In the last month alone, the return has been 10.71 %. Read More...

Investment Returns

Over 1 Month 10.71% Over 3 Months 6.94% Over 6 Months 0.47% Over 1 Year -19.62%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Shalby fundamentals


  • Market cap (Cr)

    2,182.70

  • P/E Ratio (TTM)

    27.62

  • Beta

    1.19

  • Book Value / share

    105.03

  • Return on equity

    10.22%

  • EPS (TTM)

    7.30

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    25.70

info icon alternate text
  • Market cap (Cr)

    2,177.50

  • P/E Ratio (TTM)

    27.62

  • Beta

    1.16

  • Book Value / share

    105.03

  • Return on equity

    10.22%

  • EPS (TTM)

    7.30

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    25.70

info icon alternate text

Shalby Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 236.65
Operating Expense 202.07
Net Profit 25.70
Net Profit Margin (%) 10.85
Earnings Per Share (EPS) 2.39
EBITDA 52.36
Effective Tax Rate (%) 35.93
Particulars MAR 2025 (Values in Cr)
Revenue 207.06
Operating Expense 188.52
Net Profit 14.96
Net Profit Margin (%) 7.22
Earnings Per Share (EPS) 1.39
EBITDA 37.97
Effective Tax Rate (%) 41.74
Particulars DEC 2024 (Values in Cr)
Revenue 220.64
Operating Expense 191.15
Net Profit 20.86
Net Profit Margin (%) 9.45
Earnings Per Share (EPS) 1.94
EBITDA 48.80
Effective Tax Rate (%) 41.68
Particulars SEP 2024 (Values in Cr)
Revenue 212.27
Operating Expense 189.29
Net Profit 17.34
Net Profit Margin (%) 8.16
Earnings Per Share (EPS) 1.61
EBITDA 40.76
Effective Tax Rate (%) 38.71
Particulars JUN 2024 (Values in Cr)
Revenue 232.72
Operating Expense 194.58
Net Profit 30.47
Net Profit Margin (%) 13.09
Earnings Per Share (EPS) 2.84
EBITDA 58.05
Effective Tax Rate (%) 33.52
Particulars MAR 2025 (Values in Cr)
Revenue 872.68
Operating Expense 763.38
Net Profit 83.79
Net Profit Margin (%) 9.60
Earnings Per Share (EPS) 7.80
EBITDA 185.74
Effective Tax Rate (%) 38.27
Particulars MAR 2024 (Values in Cr)
Revenue 829.68
Operating Expense 692.08
Net Profit 103.85
Net Profit Margin (%) 12.51
Earnings Per Share (EPS) 9.67
EBITDA 198.27
Effective Tax Rate (%) 34.40
Particulars MAR 2023 (Values in Cr)
Revenue 708.02
Operating Expense 606.03
Net Profit 80.81
Net Profit Margin (%) 11.41
Earnings Per Share (EPS) 7.52
EBITDA 161.51
Effective Tax Rate (%) 33.41
Particulars MAR 2022 (Values in Cr)
Revenue 646.80
Operating Expense 555.43
Net Profit 69.81
Net Profit Margin (%) 10.79
Earnings Per Share (EPS) 6.46
EBITDA 138.21
Effective Tax Rate (%) 30.13
Particulars MAR 2021 (Values in Cr)
Revenue 418.67
Operating Expense 372.78
Net Profit 42.88
Net Profit Margin (%) 10.24
Earnings Per Share (EPS) 3.97
EBITDA 95.74
Effective Tax Rate (%) 22.72
Particulars MAR 2024 (Values in Cr)
Book Value / Share 93.13
ROE % 8.66
ROCE % 11.59
Total Debt to Total Equity 0.29
EBITDA Margin 21.21
Particulars MAR 2023 (Values in Cr)
Book Value / Share 86.45
ROE % 7.50
ROCE % 10.33
Total Debt to Total Equity 0.19
EBITDA Margin 19.96
Particulars MAR 2022 (Values in Cr)
Book Value / Share 81.13
ROE % 6.31
ROCE % 8.85
Total Debt to Total Equity 0.12
EBITDA Margin 18.53
Particulars MAR 2021 (Values in Cr)
Book Value / Share 77.28
ROE % 5.19
ROCE % 6.70
Total Debt to Total Equity 0.07
EBITDA Margin 22.37
Particulars MAR 2020 (Values in Cr)
Book Value / Share 74.00
ROE % 3.49
ROCE % 7.36
Total Debt to Total Equity 0.08
EBITDA Margin 20.57
Particulars MAR 2024 (Values in Cr)
Book Value / Share 98.89
ROE % 10.22
ROCE % 14.70
Total Debt to Total Equity 0.08
EBITDA Margin 24.07
Particulars MAR 2023 (Values in Cr)
Book Value / Share 90.42
ROE % 8.61
ROCE % 12.67
Total Debt to Total Equity 0.04
EBITDA Margin 23.00
Particulars MAR 2022 (Values in Cr)
Book Value / Share 83.95
ROE % 7.95
ROCE % 11.07
Total Debt to Total Equity 0.05
EBITDA Margin 21.62
Particulars MAR 2021 (Values in Cr)
Book Value / Share 78.66
ROE % 5.16
ROCE % 6.63
Total Debt to Total Equity 0.06
EBITDA Margin 23.09
Particulars MAR 2020 (Values in Cr)
Book Value / Share 75.34
ROE % 3.48
ROCE % 7.27
Total Debt to Total Equity 0.08
EBITDA Margin 20.73
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 27.22
Total Assets 1607.53
Total Liabilities 1607.53
Total Equity 1007.78
Share Outstanding 107412505
Price to Book Ratio 2.42
Return on Assets (%) 5.23
Return on Capital (%) 6.36
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 12.28
Total Assets 1281.36
Total Liabilities 1281.36
Total Equity 927.61
Share Outstanding 107309770
Price to Book Ratio 1.49
Return on Assets (%) 5.28
Return on Capital (%) 6.33
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 110.56
Total Assets 1193.53
Total Liabilities 1193.53
Total Equity 876.18
Share Outstanding 108009770
Price to Book Ratio 1.39
Return on Assets (%) 4.53
Return on Capital (%) 5.25
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 83.57
Total Assets 996.62
Total Liabilities 996.62
Total Equity 834.67
Share Outstanding 108009770
Price to Book Ratio 1.28
Return on Assets (%) 4.25
Return on Capital (%) 4.82
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 28.73
Total Assets 966.63
Total Liabilities 966.63
Total Equity 799.20
Share Outstanding 108009770
Price to Book Ratio 0.61
Return on Assets (%) 2.85
Return on Capital (%) 3.25
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 9.22
Total Assets 1373.98
Total Liabilities 1373.98
Total Equity 1062.17
Share Outstanding 107412505
Price to Book Ratio 2.42
Return on Assets (%) 7.55
Return on Capital (%) 8.83
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.32
Total Assets 1165.65
Total Liabilities 1165.65
Total Equity 970.32
Share Outstanding 107309770
Price to Book Ratio 1.49
Return on Assets (%) 6.93
Return on Capital (%) 8.11
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 104.39
Total Assets 1087.38
Total Liabilities 1087.38
Total Equity 906.72
Share Outstanding 108009770
Price to Book Ratio 1.39
Return on Assets (%) 6.41
Return on Capital (%) 7.36
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 82.96
Total Assets 1012.25
Total Liabilities 1012.25
Total Equity 849.64
Share Outstanding 108009770
Price to Book Ratio 1.28
Return on Assets (%) 4.23
Return on Capital (%) 4.8
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 28.70
Total Assets 981.35
Total Liabilities 981.35
Total Equity 813.79
Share Outstanding 108009770
Price to Book Ratio 0.61
Return on Assets (%) 2.85
Return on Capital (%) 3.24
Particulars MAR 2024 (Values in Cr)
Net Income 128.19
Cash from Operations 39.66
Cash from Investing 38.07
Cash from Financing -150.69
Net change in Cash -93.02
Free Cash Flow 86.76
Particulars MAR 2023 (Values in Cr)
Net Income 102.04
Cash from Operations 96.18
Cash from Investing -61.07
Cash from Financing -50.00
Net change in Cash -43.30
Free Cash Flow 114.66
Particulars MAR 2022 (Values in Cr)
Net Income 79.14
Cash from Operations 41.90
Cash from Investing -60.30
Cash from Financing 90.45
Net change in Cash 49.07
Free Cash Flow 117.29
Particulars MAR 2021 (Values in Cr)
Net Income 55.05
Cash from Operations 88.24
Cash from Investing -51.26
Cash from Financing -29.85
Net change in Cash -1.97
Free Cash Flow 109.10
Particulars MAR 2020 (Values in Cr)
Net Income 56.72
Cash from Operations 75.53
Cash from Investing -30.66
Cash from Financing -21.49
Net change in Cash 3.20
Free Cash Flow 95.30
Particulars MAR 2024 (Values in Cr)
Net Income 158.31
Cash from Operations 159.53
Cash from Investing -206.00
Cash from Financing 72.13
Net change in Cash 5.90
Free Cash Flow 190.80
Particulars MAR 2023 (Values in Cr)
Net Income 121.35
Cash from Operations 191.59
Cash from Investing -172.40
Cash from Financing -38.21
Net change in Cash -46.08
Free Cash Flow 195.04
Particulars MAR 2022 (Values in Cr)
Net Income 99.92
Cash from Operations 123.73
Cash from Investing -40.31
Cash from Financing -17.24
Net change in Cash 43.36
Free Cash Flow 158.40
Particulars MAR 2021 (Values in Cr)
Net Income 55.49
Cash from Operations 86.48
Cash from Investing -51.83
Cash from Financing -27.82
Net change in Cash -2.41
Free Cash Flow 107.28
Particulars MAR 2020 (Values in Cr)
Net Income 57.02
Cash from Operations 77.10
Cash from Investing -32.27
Cash from Financing -21.49
Net change in Cash 3.31
Free Cash Flow 96.87
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 7822.15 71.48 13.70 112470.52 6002.15 / 7916.95
FORTIS MALAR HOSPITALS LIMITED 68.67 27.91 4.26 128.70 51.01 / 98.70
SHREE PACETRONIX LTD. 149.73 51.63 3.91 53.89 61.11 / 221.50
TRANSGENE BIOTEK LTD. 4.43 0.00 3.34 33.57 3.22 / 9.55
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 7822.15 83.22 12.87 112470.52 6002.15 / 7916.95
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 31.64 0.00 -12.50 23.64 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 6488.25 32.20 6.53 7098.15 4777.15 / 6525.00

Shalby Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
202.08 -0.55 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 205.10
  • 26 Days 201.50
  • 10 Days 205.10
  • 50 Days 197.60
  • 12 Days 204.90
  • 100 Days 198.50
  • 20 Days 203.00
  • 200 Days 209.90
203.41 PIVOT

First Support

199.81

First Resistance

206.79

Second Support

196.43

Second Resistance

210.39

Third Support

192.83

Third Resistance

213.77

RSI

53.04

ADX

46.91

MACD

3.40

Williams % R

-81.26

Commodity Channel Index (CCI)

-29.81

Date

2025-08-14

Week

67495.00

Same Day

100426.00

Month

129369.00

1 Year

1.20

3 Year

1.17

Over 1 Month

10.71%

down

Over 1 Year

-19.62%

down

Over 3 Months

6.94%

down

Over 3 Years

17.30%

down

Over 6 Months

0.47%

down

Over 5 Years

18.75%

down

Shalby shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
20.33%
Promoter Holdings
74.26%
FII
5.2%
DII
0.19%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Shah Family Trust Throuh Dr. Vikram Shah, Trustee 3.7517132E7 (34.73%) Shareholding of Promoter and Promoter Group
Zodiac Mediquip Limited 3.1545448E7 (29.21%) Shareholding of Promoter and Promoter Group
Vikram Indrajit Shah 8005493.0 (7.41%) Shareholding of Promoter and Promoter Group
Darshini Vikram Shah 3012525.0 (2.79%) Shareholding of Promoter and Promoter Group
First Water Fund 1909683.0 (1.77%) Public Shareholding
Shanay Vikram Shah 137525.0 (0.13%) Shareholding of Promoter and Promoter Group
Kairav Kirit Shah 250.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

Shalby corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
19 Sep 2024 1.2 Final 20 Sep 2024 Equity shares
08 Aug 2023 1.2 Final 09 Aug 2023 Equity shares
19 Sep 2022 1.0 Final 21 Sep 2022 Equity shares
17 Sep 2021 1.0 Final 21 Sep 2021 Equity shares
04 Sep 2020 0.5 Final 08 Sep 2020 Equity shares
16 Aug 2019 0.5 Final 20 Aug 2019 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
19 Sep 2024 1.2 Final 20 Sep 2024 Equity shares
08 Aug 2023 1.2 Final 09 Aug 2023 Equity shares
19 Sep 2022 1.0 Final 21 Sep 2022 Equity shares
17 Sep 2021 1.0 Final 21 Sep 2021 Equity shares
04 Sep 2020 0.5 Final 08 Sep 2020 Equity shares
16 Aug 2019 0.5 Final 20 Aug 2019 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Shalby share result highlights

Shalby’s recent financial results highlight stable growth in its healthcare operations, reflecting positive revenue and profitability. The Shalby share price reacted favourably to these results, with revenue showing an increase due to higher patient admissions and improved hospital occupancy rates. The company’s profit margins also improved, driven by cost optimisation efforts and enhanced service offerings. EBITDA growth has been strong, signalling the company’s continued focus on operational efficiency. Investors remain optimistic about Shalby’s future prospects, expecting these strong financial results to further boost the Shalby share price as the company continues to expand its presence in the healthcare sector.
 

Shalby share annual reports

Shalby’s annual reports provide a detailed view of the company’s financial health and strategic direction over the past year. The company recorded steady revenue growth, which positively impacted the Shalby share price. The balance sheet highlights the company’s strong cash flow and efficient cost management, which have contributed to a stable financial position. The annual reports also detail future plans for expanding hospital networks and enhancing patient care services, which are expected to strengthen the company’s market presence and positively affect the Shalby share price in the coming years.
 

Shalby share dividend

Shalby has maintained a consistent dividend policy, providing regular returns to shareholders. The Shalby share price responded positively to recent dividend announcements, reflecting investor confidence in the company’s financial stability. The dividend payout in the last financial year aligned with market expectations, ensuring that shareholders are rewarded while the company retains capital for future growth. Shalby’s balanced dividend approach continues to attract investor interest, supporting both shareholder value and the company’s long-term growth strategy, which positively impacts the Shalby share price.

Shalby Share Price

Shalby Limited was originally incorporated as a Private Limited Company with the name 'Shalby Hospital Private Limited' on August 30, 2004. Subsequently, the Company was converted to a Public Limited Company and the name was changed to 'Shalby Hospital Public Limited' on May 15, 2006. Further, the name of the Company was changed to Shalby Hospitals Limited on July 26, 2006 and then, again changed to Shalby Limited on February 13, 2008.

Shalby Limited is an Ahmedabad-headquartered and one of the leading multi-specialty chain of hospitals in India and provides high-quality and economical healthcare services. The Hospitals are tertiary care hospitals, few of which also offer quaternary healthcare services to patients in various areas of specialisation such as orthopaedics, complex joint replacements, cardiology, neurology, oncology, and renal transplantations.

Led by Dr. Vikram Shah, an orthopaedic surgeon, the Hospital has grown from a single hospital to a chain of multi-specialty hospitals. Apart from a focus on orthopaedics, the hospitals provide advanced levels of care across various specialties such as neurology, cardiac care, critical care, oncology, and nephrology. The Hospitals, Krishna Shalby, SG Shalby, Shalby Indore and Shalby Jabalpur are accredited by the NABH. Further, Krishna Shalby and SG Shalby are also accredited by the NABL.

The Hospital currently runs a pan-Indian chain of 11 multispecialty tertiary hospitals and 4 Single specialty Hospitals (SOCE) across 6 states with a total bed capacity of more than 2,000. Shalby has 59 outpatient clinics (OPDs) across 16 states. It also expanded global presence by opening OPDs in Kenya, Nairobi, Ethiopia, Tanzania, and Uganda in the African continent.

In 2007, the Company established operations of its first multi-specialty hospital, SG Shalby, at Sarkhej Gandhinagar Highway in Ahmedabad.

The company commenced a new hospital Shalby Vapi at Vapi in April 2012 and thereafter it commenced a new hospital Krishna Shalby in Ahmedabad in October 2012.

The company commenced a new hospital Shalby Jabalpur at Jabalpur in Madhya Pradesh in March 2015. The company commenced a new hospital Shalby Indore at Indore in August 2015.

In 2016, the company executed a memorandum of understanding with ZH Private Limited to manage and operate Zynova Shalby. During the year under review, the company executed an O&M agreement with Kamesh Hospital to commence operations of Shalby Mohali.

In 2017, the company entered into an agreement with Bait Al Batterjee Medical Company LLC, Dubai, to provide outpatient orthopaedics and spine surgeries.

The Company came up with an Initial Public Offer of 20,354,838 Equity Shares by raising capital from public aggregating to Rs 504. 8 Crores comprising a Fresh Issue of 19,354,838 Equity Shares amounting to Rs 480 Crores and an Offer for Sale of 1,000,000 Equity Shares amounting to Rs 24.8 Crore in December, 2017.

With the increase in demand of digital transformation in healthcare sector, Shalby embarked its journey of digital transformation across its all hospitals from 2018-19. In 2020, the Company launched Video Assisted Thoracic Surgery (VATS) to reduce the incidence of surgical complications. The Liver Transplant Facility became fully operational at Shalby, Ahmedabad and Mohali.

The Company incorporated a new wholly owned subsidiary Company under the name and style Mars Medical Devices Limited' on April 3, 2020. The Company also incorporated wholly-owned subsidiary company under the name and style Shalby Hospitals Mumbai Pvt. Ltd.' on December 10, 2020. In May 2021, the Company acquired the assets of Consensus Orthopaedics, a hip and knee implant manufacturing company with its facility at El Dorado Hills, USA. The Company also commenced multi-speciality rehabilitation centre at one of its Unit in 2021.

The Company launched a state-of-the-art Digital Spine Operation Room' at SG Shalby Hospital, Ahmedabad in 2022. In September 2021, the Company launched its first Shalby Orthopedics Centre of Excellence (SOCE) in the country at Udaipur. Centralised cloud based Laboratory Information System (LIS) was launched in 2022. The Company further incorporated Shalby Advanced Technologies Inc. (SAT) in the first quarter of Fiscal 2022.

In 2022-23, the Company launched a new product line of Uni Knee System called as Tahoe Unicompartmental Knee System or TUKS.
It acquired 87.26% stake in PK Healthcare Pvt Ltd (Sanar International Hospital-130 beds) in FY 2024, making it a subsidiary of the Company and has further acquired 100% stake in Healers Hospital Pvt Ltd at Gurugram costing Rs 104 Crore. Company further has established new SOCE in Ranchi having 60 beds in 2024.

Parent organization Indian Private
NSE symbol SHALBY
Founded 2004
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Shalby Ltd?

Answer Field

Shalby Ltd share price is for NSE ₹ 202.08 & for BSE ₹ 201.50 as on Aug 18 2025 03:30 PM.

What is the Market Cap of Shalby Ltd Share?

Answer Field

The market cap of Shalby Ltd for NSE ₹ 2,170.59 & for BSE ₹ 2,164.36 as on Aug 18 2025 03:30 PM.

What is the 52 Week High and Low of Shalby Ltd?

Answer Field

The 52 Week High and Low of Shalby Ltd for NSE is ₹ 297.90 and ₹ 177.25 and for BSE is ₹ 297.00 and ₹ 177.20.

What is 1 year return for Shalby Ltd?

Answer Field

The 1 year returns on the stock has been -19.62%.

What is the P/E Ratio of Shalby Ltd Share?

Answer Field

As on Aug 18 2025 03:30 PM the price-to-earnings (PE) ratio for Shalby Ltd share is 27.62.

What is the PB ratio of Shalby Ltd Share?

Answer Field

As on Aug 18 2025 03:30 PM, the price-to-book (PB) ratio for Shalby Ltd share is 105.03.

How to Buy Shalby Ltd Share?

Answer Field

You can trade in Shalby Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Shalby Ltd Share on Bajaj Broking App?

Answer Field

To buy Shalby Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Shalby Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Shalby?

Answer Field

The CEO of Shalby is responsible for leading the company’s strategic vision and overseeing its healthcare operations. Under their leadership, Shalby has continued to grow and expand its presence in the healthcare industry. The CEO’s focus on enhancing service quality and operational efficiency has contributed to the company’s positive financial performance, which has had a direct influence on the Shalby share price. Investors watch the CEO’s decisions closely to assess the company’s future prospects.

When was Shalby established?

Answer Field

Shalby was established several decades ago, entering the healthcare sector with a focus on providing quality medical services. Since its inception, the company has grown steadily, contributing to the rise in the Shalby share price. Over the years, Shalby has expanded its hospital network and diversified its service offerings, becoming a recognised name in the healthcare industry. The company’s establishment laid the foundation for its current success and continued market presence.

What factors influence the Shalby share price?

Answer Field

Several factors influence the Shalby share price, including the company’s financial performance, patient admissions, and operational efficiency. Internal factors such as revenue growth, profitability, and service expansion also play a critical role. External factors like industry trends, healthcare demand, and government policies further impact the share price. Investors carefully monitor these variables to assess potential movements in the Shalby share price and make informed decisions based on market and company performance.

Is Shalby debt free?

Answer Field

Shalby is not entirely debt-free but maintains a manageable level of debt that supports its growth and expansion plans. The company’s financial reports reflect that its debt levels are well-controlled and do not pose significant risks to its operations. This prudent debt management strategy positively impacts investor confidence and the Shalby share price, as the company continues to maintain financial stability while pursuing growth opportunities in the healthcare sector.

How has the Shalby share price performed over the past year?

Answer Field

The Shalby share price has experienced moderate fluctuations over the past year, influenced by the company’s financial performance and broader market conditions. While the share price saw periods of growth driven by strong earnings and hospital expansions, it also faced some volatility due to external factors. Overall, the Shalby share price has remained stable, reflecting the company’s solid position in the healthcare industry. Investors continue to monitor the company’s performance closely for future growth potential.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|